FDA Delays Approval Of Pfizer-BMS Anti-Clotting Drug
The U.S. Food and Drug Administration has given itself three more months to review new data before deciding whether to approve an drug designed to reduce the risk of blood clots...To view the full article, register now.
Already a subscriber? Click here to view full article